Jiao Shen

Jiao Shen

Auto-generated profile, based on publicly available information

Jiao Shen

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JSJiao Shen
Jiao Shen
ZZZhuangzhi Zou
Zhuangzhi Zou
JGJingya Guo
Jingya Guo
YCYueqi Cai
Yueqi Cai
DXDiyuan Xue
Diyuan Xue
YFYang-Xin Fu
Yang-Xin Fu
Checkpoint blockade immunotherapy releases the inhibition of tumor-infiltrating lymphocytes (TILs) but weakly induces TIL proliferation. Exogenous IL-15 could further expand TILs and thus synergize with αPD-L1 therapy. However, systemic delivery of IL-15 extensively expands peripheral NK cells, causing severe toxicity. To redirect IL-15 to intratumoral PD-1+CD8+T effector cells instead of NK cells for better tumor control and lower toxicity, we engineered an anti–PD-1 fusion with IL-15-IL-15Rα, whose activity was geographically concealed by immunoglobulin Fc region with an engineered linker (αPD-1-IL-15-R) to bypass systemic NK cells. Systematic administration of αPD-1-IL-15-R elicited extraordinary antitumor efficacy with undetectable toxicity. Mechanistically, cis-delivery of αPD-1-IL-15-R vastly expands tumor-specific CD8+T cells for tumor rejection. Additionally, αPD-1-IL-15-R upregulated PD-1 and IL-15Rβ on T cells to create a feedforward activation loop, thus rejuvenating TILs, not only resulting in tumor control in situ, but also suppressing tumor metastasis. Collectively, renavigating IL-15 to tumor-specific PD-1+CD8+T cells, αPD-1-IL-15-R elicits effective systemic antitumor immunity.

3 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZZZhuangzhi Zou
Zhuangzhi Zou
JSJiao Shen
Jiao Shen
DXDiyuan Xue
Diyuan Xue
HLHongjia Li
Hongjia Li
LXLongxin Xu
Longxin Xu
HPHua Peng
Hua Peng
Immune checkpoint blockade (ICB) therapies function by alleviating immunosuppression on tumor-infiltrating lymphocytes (TILs) but are often insufficient to fully reactivate these dysfunctional TILs. Although interleukin 12 (IL-12) has been used in combination with ICB to improve efficacy, this remains limited by severe toxicity associated with systemic administration of this cytokine. Here, we engineer a fusion protein composed of an anti-PD-1 antibody and a mouse low-affinity IL-12 mutant-2 (αPD1-mIL12mut2). Systemic administration of αPD1-mIL12mut2 displays robust antitumor activities with undetectable toxicity. Mechanistically, αPD1-mIL12mut2 preferentially activates tumor-infiltrating PD-1+CD8+T cells via high-affinity αPD-1 mediated cis-binding of low-affinity IL-12. Additionally, αPD1-mIL12mut2 treatment exerts an abscopal effect to suppress distal tumors, as well as metastasis. Collectively, αPD1-mIL12mut2 treatment induces robust systemic antitumor responses with reduced side effects.

14 May 2026 in Science
Verified
Journal Article
Open access
GRGrayson E. Rodriguez
Grayson E. Rodriguez
YZYang Zhao
Yang Zhao
YNYoko Nishiga
Yoko Nishiga
FPFrank Peprah
Frank Peprah
JSJiao Shen
Jiao Shen
KGK. Christopher Garcia
K. Christopher Garcia
Cytokines dimerize two receptor chains to activate Janus kinases and signal transducer and activator of transcription (STAT) transcription factors that regulate immune cells, but they have therapeutic liabilities. We engineered “Trikines” to compel cis formation of three-chain cytokine receptor complexes at the cell surface that induce bespoke STAT transcriptional signaling programs. Trikines coactivated phosphorylation of STAT5 (pSTAT5) and pSTAT3 signatures distinct from natural cytokines by assembling trimeric combinations of interleukin-2 (IL-2), IL-10, and IL-21 receptors. In preclinical models, an IL-2–based Trikine restrained terminal differentiation of T cells, promoted stemness, and enhanced durability of tumor control without observable toxicity. An IL-10–based Trikine induced immune infiltration into poorly immunogenic tumors, showing efficacy in preclinical models of small cell lung cancer and pancreatic cancer. Trikines obviate the need for cell engineering to customize STAT signatures and may hold potential for immunotherapy.

12 June 2025 in Cancer Immunology Research
Verified
Journal Article
Open access
MWMichael Wichroski
Michael Wichroski
SLSi-Qi Liu
Si-Qi Liu
LZLauren M. Zasadil
Lauren M. Zasadil
JBJoseph L. Benci
Joseph L. Benci
PGPatrick C. Gedeon
Patrick C. Gedeon
ELEmma Lees
Emma Lees
Diacylglycerol kinase α (DGKα) and DGKζ are lipid kinases that negatively regulate T-cell signaling through diacylglycerol metabolism, making them attractive targets for next-generation immunotherapy. In this study, we report the discovery and preclinical characterization of the clinical-stage DGKα and DGKζ lipid kinase inhibitor, BMS-986408. BMS-986408 binds to the accessory subdomain of the catalytic domain and inhibits DGKα/ζ through a mechanism of action that includes competitive inhibition for the diacylglycerol substrate, subcellular translocation to the plasma membrane, and proteosome-dependent degradation. DGKα/ζ inhibition markedly improved the therapeutic benefit of PD-1 therapy by unleashing T-cell responses in the tumor while also amplifying the priming and expansion of tumor-reactive T cells in tumor-draining lymph nodes. Simultaneous inhibition of both DGKα and DGKζ was required to maximize combination benefit with PD-1 therapy. Furthermore, we observed in non–small cell lung cancer (NSCLC) patient samples that DGKα and DGKζ were broadly expressed in tumor-infiltrated T cells and that combination therapy invigorated a robust cytokine response in organotypic tumors derived from patients with NSCLC, supporting the clinical evaluation of this combination in patients with NSCLC. BMS-986408 also markedly improved CD19-targeted CAR T-cell therapy efficacy by overcoming hypofunctionality, insufficient expansion, and lack of costimulatory ligands. BMS-986408 represents a critical step toward evaluating the broad immunotherapy potential of DGKα/ζ inhibitors in patients with cancer.

2 September 2025
Verified
Other
Open access
PDF file
MWMichael Wichroski
Michael Wichroski
SLSi-Qi Liu
Si-Qi Liu
LZLauren M. Zasadil
Lauren M. Zasadil
JBJoseph L. Benci
Joseph L. Benci
PGPatrick C. Gedeon
Patrick C. Gedeon
ELEmma Lees
Emma Lees
Fig. S3. Antigen specific T cell response in the CT26 model.

2 September 2025
Verified
Other
Open access
MWMichael Wichroski
Michael Wichroski
SLSi-Qi Liu
Si-Qi Liu
LZLauren M. Zasadil
Lauren M. Zasadil
JBJoseph L. Benci
Joseph L. Benci
PGPatrick C. Gedeon
Patrick C. Gedeon
ELEmma Lees
Emma Lees
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies